Announcements

Job offersmore »



Tweeting Growers

Top 5 - yesterday

  • No news has been published yesterday.

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




CAN (ON): Aphria inks wholesale supply deal with Scientus Pharma

Aphria, through its subsidiary Pure Natures Wellness, entered into a major wholesale supply agreement with HydRx Farms. Under the terms of the Agreement, Aphria is committing to supply over 25,000 fully grown medical cannabis plants over the next 12 months to Scientus Pharma. The first delivery, under the agreement will occur in the middle of Aphria’s second quarter of 2018. Aphria expects to generate over $1.2 million of revenue from the wholesale supply agreement in each full quarter of
shipments, with gross margins consistent with previously executed wholesale agreements.



Scientus Pharma, a vertically-integrated biopharmaceutical company, is raising the bar of cannabinoid products from medical-grade to pharmaceutical-grade. Leveraging its proprietary, patent-pending formulation and processing technologies, Scientus Pharma is committed to leading the medical cannabis market towards pharmaceutical standards in manufacturing, formulations and dosing.

“Scientus Pharma shares our vision for providing high-quality products to medical cannabis patients, which is enabled by our 509-step Seed-to Sale quality assurance program,” said Vic Neufeld, Chief Executive Officer of Aphria. “Through this agreement, Scientus Pharma will get access to clean and safe cannabis, which is necessary in the biopharmaceutical cannabis industry. In return, Aphria will benefit from guaranteed product distribution advancing Aphria’s growth strategy.”

“Scientus Pharm intends to leverage this key raw material supply contract to help it lead the evolution of cannabinoid products from medical-grade to pharmaceutical-grade,” said Trevor Folk, Chief Executive Officer of Scientus Pharma. “Our proprietary extraction technology platform has solved the resin consistency issue that has here-to-for prevented that scientific advancement, and it is the foundation for Scientus Pharma’s pipeline of novel products.”

For more information:
Aphria Inc.
Vic Neufeld
President & CEO
1-844-427-4742
aphria.com

Scientus Pharma
209 Dundas St. E
PO Box 31 Whitby
Whitby, ON L1N 5R7
T: +1 844 493.7922
info@scientuspharma.com
scientuspharma.com

Publication date: 7/6/2017

 


 

Other news in this sector:

11/17/2017 CAN (BC): Should Delta get a share of lucrative pot bucks?
11/16/2017 Vancouver firm eyes Uruguayan MMJ market
11/16/2017 MedReleaf Australia receives cultivation license
11/16/2017 Jamaica: MMJ companies form alliance
11/16/2017 IBM wants British Columbia to track legal pot with blockchain tech
11/15/2017 Greece hopes to boost economy with MMJ
11/15/2017 Aurora Cannabis plans to take over CanniMed
11/15/2017 US (CA): Cannabis growers could face taxes on destroyed crops
11/14/2017 US (NV): Grower hits record-breaking THC & terpene profiles
11/14/2017 US (CA): Coachella City approves cannabis greenhouse facility
11/13/2017 Canada: Supreme commences production in new flowering rooms
11/10/2017 CAN (ON): Beleave to expand with 80,000 sq. ft. in Hamilton
11/10/2017 Macedonian MMJ grower invests in LED
11/9/2017 Academic research into HPS vs. LED for cannabis cultivation
11/8/2017 Maximizing cannabis yields using controlled environment technology
11/8/2017 US (OH): Provisional licenses for Level II marijuana cultivators
11/8/2017 US (ME): Marijuana grower develops mechanical farmhand
11/8/2017 CAN (QC): Aurora receives cultivation license for Pointe-Claire site
11/7/2017 Biotech company and UC Davis to unravel cannabis genomics
11/7/2017 "Strong increase in cannabis production with bubble oxygenation"